Immuron (IMRN) Depreciation & Amortization (CF) (2020 - 2021)
Immuron (IMRN) recorded quarterly Depreciation & Amortization (CF) of $33622.1 in Q2 2021, up 16.44% quarter-over-quarter from $28875.2 in Q2 2020, and up 16.44% on a YoY basis from $28875.2 in Q2 2020.
Immuron (IMRN) Depreciation & Amortization (CF) (2020 - 2021) Analysis & Trends
Immuron's Depreciation & Amortization (CF) history runs 2 years deep, the most recent figure standing at $33622.1 for Q2 2021.
- In Q2 2021, Depreciation & Amortization (CF) rose 16.44% year-over-year to $33622.1; the TTM figure through Aug 2022 stood at $33622.1 (changed N/A YoY), while the FY2025 annual figure was $32204.2, up 6.79% from the prior year.
- Depreciation & Amortization (CF) was $33622.1 for Q2 2021 at Immuron, up from $28875.2 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $33622.1 in Q2 2021 to a low of $28875.2 in Q2 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 1,395.22 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1,330.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 55.90 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 429,663.65 |
| 10 | Immuron | 921.61 Mn | 921.58 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 33,622.15 |
| Jun 30, 2021 | 33,622.15 |
| Jun 30, 2020 | 28,875.21 |
| Jun 30, 2020 | 28,875.21 |